Cargando…
High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine
Autores principales: | McNamara, Lucy A., Topaz, Nadav, Wang, Xin, Hariri, Susan, Fox, LeAnne, MacNeil, Jessica R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5687588/ https://www.ncbi.nlm.nih.gov/pubmed/28704351 http://dx.doi.org/10.15585/mmwr.mm6627e1 |
Ejemplares similares
-
Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States
por: Bozio, Catherine H., et al.
Publicado: (2020) -
University-Based Outbreaks of Meningococcal Disease Caused by Serogroup B, United States, 2013–2018
por: Soeters, Heidi M., et al.
Publicado: (2019) -
Meningococcal Disease Surveillance in Men Who Have Sex with Men — United States, 2015–2016
por: Bozio, Catherine H., et al.
Publicado: (2018) -
Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan
por: Tanimoto, Tetsuya, et al.
Publicado: (2014) -
Genetic Features of a Representative Panel of 110 Meningococcal B Isolates to Assess the Efficacy of Meningococcal B Vaccines
por: Muzzi, Alessandro, et al.
Publicado: (2022)